A recent study found that rituximab maintenance therapy provides no additional benefit for patients with diffuse large B‐cell lymphoma (DLBCL) who are in complete remission after receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy.
A recent study found that rituximab maintenance therapy provides no additional benefit for patients with diffuse large B‐cell lymphoma (DLBCL) who are in complete remission (CR) after receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy.
The randomized phase 3 trial from the Netherlands assessed whether intensification of rituximab during the first 4 cycles of CHOP can improve outcomes, compared with standard R‐CHOP. It was previously shown that intensification of rituximab was not more effective than standard CHOP, showing same CR‐rates and progression free survival (PFS) after induction.
This study looked at the second randomization for rituximab maintenance therapy. Patients in CR after induction treatment were randomized between rituximab maintenance and observation. According to the trial registry, the patient population included previously untreated patients aged 66 to 80 years with stage 2 to stage 4 DLBCL and CD20-positive B cells.
Researchers randomized patients between 24 months of rituximab maintenance at a dose of 375 mg/m2 intravenously every 8 weeks (n = 199 ) or observation (n = 199). Computerized tomography scans were performed at 6, 12, 18 and 24 months in both arms.
The primary endpoint was disease-free survival (DFS) from maintenance randomization; secondary endpoints were overall survival (OS) and adverse events (AEs).
The majority of patients (54%) had a high‐intermediate or high age-adjusted International Prognostic Index (aaIPI) score. Nearly half were male with a median age of 65 years (range 31‐80); 48% were 66 years or older.
After a median follow‐up of 79.9 months (maximum 125.7 months), the 5‐year DFS rate was 79% for rituximab maintenance versus 74% for observation.
This difference was not statistically significant, with a hazard ratio of 0.83 (95% confidence interval 0.57‐1.19, P = .31, adjusted for age and aa‐IPI).
The secondary endpoint of OS was also not significantly different (85% versus 83% at 5 years).
In addition, no clinical subgroup benefited from rituximab maintenance.
Toxicity was mild; grade 3 and 4 AEs were reported in 17% and 6% of patients, respectively. Infection was the most frequent AE; neutropenia was seen in 1% (grade 3) and 3% (grade 4) of patients.
Reference
Lugtenburg P, de Nully Brown P, van der Holt B, et al. Rituximab maintenance for patients with diffuse large B‐cell lymphoma in first complete remission: results from a randomized Hovon‐Nordic lymphoma group phase III study. Presented at: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi, June 18-22, 2019; Lugano, Switzerland. Abstract 043.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Bevacizumab Biosimilars Offer Promise for CRC Treatment, Wound Healing, and Cost Savings
February 28th 2024A review emphasizes that bevacizumab biosimilars demonstrate comparable efficacy to the reference product (Avastin) in the treatment of colorectal cancer (CRC) by tackling wound healing concerns in anorectal medicine.